Azathioprine


Generic Medicine Info
Administration
May be taken with or without food. Preferably taken w/ or after meals to reduce GI discomfort.
Contraindications
History of treatment w/ alkylating agents (e.g. chlorambucil, cyclophosphamide).
Special Precautions
Patient who are intermediate or poor thiopurine methyltransferase (TPMT) metabolisers. Patient with NUDT15 gene mutation. Renal and hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor CBC w/ differential and platelet regularly, LFTs, total bilirubin, CrCl, symptoms of infection; TPMT genotyping or phenotyping.
Adverse Reactions
Bone marrow depression (dose-related) characterised by anaemia, leucopenia, thrombocytopenia and rarely, aplastic anaemia, agranulocytosis, pancytopenia; reversible myelosuppression, megaloblastic anaemia, myelotoxicity, liver damage, GI disturbances, reversible alopecia, rashes, muscle and joint pains, rigors, fever, pneumonitis, tachycardia, pancreatitis, renal dysfunction, hypotension, Sweet's syndrome (acute febrile neutrophilic dermatosis). Rarely, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Potentially Fatal: Progressive multifocal leucoencephalopathy. Rarely, veno-occlusive liver disease, hepatosplenic T-cell lymphoma (HSTCL), post-transplant lymphoma.
Drug Interactions
Increased risk of infection w/ intra-uterine device and live vaccine. May potentiate neuromuscular blockade produced by depolarising agents (e.g. succinylcholine). May reduce neuromuscular blockade by non-depolarising agents (e.g. tubocurarine). May reduce anticoagulant effect of warfarin. Risk of haematologic abnormalities w/ ACE inhibitors, co-trimoxazole. Increased myelosuppressive effects w/ indometacin and cimetidine. Decreased rate of catabolism w/ xanthine oxidase inhibitors (e.g. allopurinol). Ribavirin may reduce efficacy and increase toxicity of azathioprine.
CIMS Class
ATC Classification
L04AX01 - azathioprine ; Belongs to the class of other immunosuppressants.
Disclaimer: This information is independently developed by CIMS based on azathioprine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in